Porphyria cutanea tarda

From IDWiki
Revision as of 01:17, 4 July 2020 by Maintenance script (talk | contribs) (Imported from text file)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Definition

  • A defect in the heme synthesis pathway that causes cutaneous manifestations in adults
  • Either type 1 (sporadic) or type 2 (familial)

Pathophysiology

  • A defect in uroporphyrinogen decarboxylase, which normally converts uroporphyrinogen I and III to coproporphyrinogen I and III

Clinical Presentation

  • Blistering skin lesions on the back of the hands
    • They rupture and crust over, leaving atrophy and scarring
    • Scarring and calcification can look like sclerosis
  • Lesions may appear on forearms, face, legs, and feet
  • May have hyperpigmentation and hypertrichosis of the face
  • No neurological manifestations
  • Often have liver disease, and are higher risk for hepatocellular carcinoma

Investigations

  • Porphyrins in liver, plasma, urine, or stool are elevated
    • Urinary porphyrins include uroporphyrins and heptacarboxylate porphyrin
  • Urinary ALA level may be elevated
  • PBG level is normal

Management

  • Avoid alcohol
  • Stop estrogen supplements, iron supplements, and any other drugs that may be exacerbating
  • Repeated phlebotomy to reduce hepatic iron stores
    • Remove 1 unit every 1 to 2 weeks
    • Remission may require more than six phlebotomies
    • Follow the serum porphyrin levels every 6 to 12 months; they should decrease
  • Hydroxychloroquine is second-line
  • Liver imaging to screen for hepatocellular carcinoma